ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Research Report 2024
Published Date: December 2024
|
Report Code: QYRE-Auto-16Z18752
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Research Report 2024
BUY CHAPTERS

Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Research Report 2024

Code: QYRE-Auto-16Z18752
Report
December 2024
Pages:76
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amgen Inc
Sanofi SA
Innovent Biologics, Inc.
Shanghai Junshi Biosciences Co.,Ltd
Akeso Biopharma Co., Ltd

Monoclonal Antibodies for Primary Hypercholesterolemia Market Size

The global market for Monoclonal Antibodies for Primary Hypercholesterolemia was valued at US$ 2279 million in the year 2023 and is projected to reach a revised size of US$ 6920 million by 2030, growing at a CAGR of 17.2% during the forecast period.

Monoclonal Antibodies for Primary Hypercholesterolemia Market

Monoclonal Antibodies for Primary Hypercholesterolemia Market

Monoclonal antibodies for primary hypercholesterolemia are a class of monoclonal antibody drugs that target proprotein convertase subtilis subtilis /kexin 9 (PCSK9). By specifically binding to PCSK9, they prevent its binding to the low-density lipoprotein receptor (LDL-R), thereby reducing the degradation of LDL-R, increasing the clearance of LDL-C, and significantly reducing the level of low-density lipoprotein cholesterol (LDL-C) in the blood. These agents are used primarily to treat adult patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia and nonfamilial hypercholesterolemia, and mixed dyslipidemia.
North American market for Monoclonal Antibodies for Primary Hypercholesterolemia is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Monoclonal Antibodies for Primary Hypercholesterolemia is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Monoclonal Antibodies for Primary Hypercholesterolemia include Amgen, Inc., Sanofi SA, Innovent Biologics, Inc, Akeso Biopharma Co., Ltd, Shanghai Junshi Biosciences Co., Ltd, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibodies for Primary Hypercholesterolemia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibodies for Primary Hypercholesterolemia.
The Monoclonal Antibodies for Primary Hypercholesterolemia market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Monoclonal Antibodies for Primary Hypercholesterolemia market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Monoclonal Antibodies for Primary Hypercholesterolemia manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Monoclonal Antibodies for Primary Hypercholesterolemia Market Report

Report Metric Details
Report Name Monoclonal Antibodies for Primary Hypercholesterolemia Market
Accounted market size in year US$ 2279 million
Forecasted market size in 2030 US$ 6920 million
CAGR 17.2%
Base Year year
Forecasted years 2025 - 2030
by Type
  • 140 mg/mL
  • 150 mg/mL
  • 300 mg/mL
by Application
  • Hospital
  • Clinic
  • Others
Production by Region
  • North America
  • Europe
  • China
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amgen, Inc., Sanofi SA, Innovent Biologics, Inc, Akeso Biopharma Co., Ltd, Shanghai Junshi Biosciences Co., Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Monoclonal Antibodies for Primary Hypercholesterolemia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Monoclonal Antibodies for Primary Hypercholesterolemia in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Monoclonal Antibodies for Primary Hypercholesterolemia Market growing?

Ans: The Monoclonal Antibodies for Primary Hypercholesterolemia Market witnessing a CAGR of 17.2% during the forecast period 2025-2030.

What is the Monoclonal Antibodies for Primary Hypercholesterolemia Market size in 2030?

Ans: The Monoclonal Antibodies for Primary Hypercholesterolemia Market size in 2030 will be US$ 6920 million.

Who are the main players in the Monoclonal Antibodies for Primary Hypercholesterolemia Market report?

Ans: The main players in the Monoclonal Antibodies for Primary Hypercholesterolemia Market are Amgen, Inc., Sanofi SA, Innovent Biologics, Inc, Akeso Biopharma Co., Ltd, Shanghai Junshi Biosciences Co., Ltd

What are the Application segmentation covered in the Monoclonal Antibodies for Primary Hypercholesterolemia Market report?

Ans: The Applications covered in the Monoclonal Antibodies for Primary Hypercholesterolemia Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Monoclonal Antibodies for Primary Hypercholesterolemia Market report?

Ans: The Types covered in the Monoclonal Antibodies for Primary Hypercholesterolemia Market report are 140 mg/mL, 150 mg/mL, 300 mg/mL

Recommended Reports

Monoclonal Antibody Drugs

Cholesterol & Lipid Drugs

Targeted & Therapeutic Drugs

1 Monoclonal Antibodies for Primary Hypercholesterolemia Market Overview
1.1 Product Definition
1.2 Monoclonal Antibodies for Primary Hypercholesterolemia by Type
1.2.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Value Comparison by Type (2024-2030)
1.2.2 140 mg/mL
1.2.3 150 mg/mL
1.2.4 300 mg/mL
1.3 Monoclonal Antibodies for Primary Hypercholesterolemia by Application
1.3.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Size Estimates and Forecasts
1.4.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue 2019-2030
1.4.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales 2019-2030
1.4.3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Monoclonal Antibodies for Primary Hypercholesterolemia Market Competition by Manufacturers
2.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Manufacturers (2019-2024)
2.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Monoclonal Antibodies for Primary Hypercholesterolemia, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Monoclonal Antibodies for Primary Hypercholesterolemia, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Monoclonal Antibodies for Primary Hypercholesterolemia, Product Type & Application
2.7 Global Key Manufacturers of Monoclonal Antibodies for Primary Hypercholesterolemia, Date of Enter into This Industry
2.8 Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Competitive Situation and Trends
2.8.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Monoclonal Antibodies for Primary Hypercholesterolemia Players Market Share by Revenue
2.8.3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Scenario by Region
3.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region: 2019-2030
3.2.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region: 2019-2024
3.2.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region: 2025-2030
3.3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region: 2019-2030
3.3.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region: 2019-2024
3.3.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region: 2025-2030
3.4 North America Monoclonal Antibodies for Primary Hypercholesterolemia Market Facts & Figures by Country
3.4.1 North America Monoclonal Antibodies for Primary Hypercholesterolemia Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2019-2030)
3.4.3 North America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Monoclonal Antibodies for Primary Hypercholesterolemia Market Facts & Figures by Country
3.5.1 Europe Monoclonal Antibodies for Primary Hypercholesterolemia Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2019-2030)
3.5.3 Europe Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Market Facts & Figures by Region
3.6.1 Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region (2019-2030)
3.6.3 Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Market Facts & Figures by Country
3.7.1 Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2019-2030)
3.7.3 Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Market Facts & Figures by Country
3.8.1 Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2019-2030)
3.8.3 Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Type (2019-2030)
4.1.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Type (2019-2024)
4.1.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Type (2025-2030)
4.1.3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Type (2019-2030)
4.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Type (2019-2030)
4.2.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Type (2019-2024)
4.2.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Type (2025-2030)
4.2.3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Type (2019-2030)
4.3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Price by Type (2019-2030)
5 Segment by Application
5.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Application (2019-2030)
5.1.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Application (2019-2024)
5.1.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Application (2025-2030)
5.1.3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Application (2019-2030)
5.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Application (2019-2030)
5.2.1 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Application (2019-2024)
5.2.2 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Application (2025-2030)
5.2.3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Application (2019-2030)
5.3 Global Monoclonal Antibodies for Primary Hypercholesterolemia Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen, Inc.
6.1.1 Amgen, Inc. Company Information
6.1.2 Amgen, Inc. Description and Business Overview
6.1.3 Amgen, Inc. Monoclonal Antibodies for Primary Hypercholesterolemia Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen, Inc. Monoclonal Antibodies for Primary Hypercholesterolemia Product Portfolio
6.1.5 Amgen, Inc. Recent Developments/Updates
6.2 Sanofi SA
6.2.1 Sanofi SA Company Information
6.2.2 Sanofi SA Description and Business Overview
6.2.3 Sanofi SA Monoclonal Antibodies for Primary Hypercholesterolemia Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi SA Monoclonal Antibodies for Primary Hypercholesterolemia Product Portfolio
6.2.5 Sanofi SA Recent Developments/Updates
6.3 Innovent Biologics, Inc
6.3.1 Innovent Biologics, Inc Company Information
6.3.2 Innovent Biologics, Inc Description and Business Overview
6.3.3 Innovent Biologics, Inc Monoclonal Antibodies for Primary Hypercholesterolemia Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Innovent Biologics, Inc Monoclonal Antibodies for Primary Hypercholesterolemia Product Portfolio
6.3.5 Innovent Biologics, Inc Recent Developments/Updates
6.4 Akeso Biopharma Co., Ltd
6.4.1 Akeso Biopharma Co., Ltd Company Information
6.4.2 Akeso Biopharma Co., Ltd Description and Business Overview
6.4.3 Akeso Biopharma Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Akeso Biopharma Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Product Portfolio
6.4.5 Akeso Biopharma Co., Ltd Recent Developments/Updates
6.5 Shanghai Junshi Biosciences Co., Ltd
6.5.1 Shanghai Junshi Biosciences Co., Ltd Company Information
6.5.2 Shanghai Junshi Biosciences Co., Ltd Description and Business Overview
6.5.3 Shanghai Junshi Biosciences Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Shanghai Junshi Biosciences Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Product Portfolio
6.5.5 Shanghai Junshi Biosciences Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Monoclonal Antibodies for Primary Hypercholesterolemia Industry Chain Analysis
7.2 Monoclonal Antibodies for Primary Hypercholesterolemia Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Monoclonal Antibodies for Primary Hypercholesterolemia Production Mode & Process
7.4 Monoclonal Antibodies for Primary Hypercholesterolemia Sales and Marketing
7.4.1 Monoclonal Antibodies for Primary Hypercholesterolemia Sales Channels
7.4.2 Monoclonal Antibodies for Primary Hypercholesterolemia Distributors
7.5 Monoclonal Antibodies for Primary Hypercholesterolemia Customers
8 Monoclonal Antibodies for Primary Hypercholesterolemia Market Dynamics
8.1 Monoclonal Antibodies for Primary Hypercholesterolemia Industry Trends
8.2 Monoclonal Antibodies for Primary Hypercholesterolemia Market Drivers
8.3 Monoclonal Antibodies for Primary Hypercholesterolemia Market Challenges
8.4 Monoclonal Antibodies for Primary Hypercholesterolemia Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Amgen Inc
Sanofi SA
Innovent Biologics, Inc.
Shanghai Junshi Biosciences Co.,Ltd
Akeso Biopharma Co., Ltd
List of Tables
 Table 1. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units) of Key Manufacturers (2019-2024)
 Table 5. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Monoclonal Antibodies for Primary Hypercholesterolemia Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Monoclonal Antibodies for Primary Hypercholesterolemia, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Monoclonal Antibodies for Primary Hypercholesterolemia, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Monoclonal Antibodies for Primary Hypercholesterolemia, Product Type & Application
 Table 12. Global Key Manufacturers of Monoclonal Antibodies for Primary Hypercholesterolemia, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Monoclonal Antibodies for Primary Hypercholesterolemia by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibodies for Primary Hypercholesterolemia as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region (2019-2024) & (Units)
 Table 18. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Region (2019-2024)
 Table 19. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region (2025-2030) & (Units)
 Table 20. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Region (2025-2030)
 Table 21. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Region (2019-2024)
 Table 23. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Region (2025-2030)
 Table 25. North America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2019-2024) & (Units)
 Table 27. North America Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2025-2030) & (Units)
 Table 28. North America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2019-2024) & (Units)
 Table 32. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2025-2030) & (Units)
 Table 33. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region (2019-2024) & (Units)
 Table 37. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Region (2025-2030) & (Units)
 Table 38. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2019-2024) & (Units)
 Table 42. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2025-2030) & (Units)
 Table 43. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2019-2024) & (Units)
 Table 47. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Sales by Country (2025-2030) & (Units)
 Table 48. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units) by Type (2019-2024)
 Table 51. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units) by Type (2025-2030)
 Table 52. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Type (2019-2024)
 Table 53. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Type (2025-2030)
 Table 54. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Type (2019-2024)
 Table 57. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Type (2025-2030)
 Table 58. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units) by Application (2019-2024)
 Table 61. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units) by Application (2025-2030)
 Table 62. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Application (2019-2024)
 Table 63. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Application (2025-2030)
 Table 64. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Application (2019-2024)
 Table 67. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Application (2025-2030)
 Table 68. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Application (2025-2030)
 Table 70. Amgen, Inc. Company Information
 Table 71. Amgen, Inc. Description and Business Overview
 Table 72. Amgen, Inc. Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Amgen, Inc. Monoclonal Antibodies for Primary Hypercholesterolemia Product
 Table 74. Amgen, Inc. Recent Developments/Updates
 Table 75. Sanofi SA Company Information
 Table 76. Sanofi SA Description and Business Overview
 Table 77. Sanofi SA Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Sanofi SA Monoclonal Antibodies for Primary Hypercholesterolemia Product
 Table 79. Sanofi SA Recent Developments/Updates
 Table 80. Innovent Biologics, Inc Company Information
 Table 81. Innovent Biologics, Inc Description and Business Overview
 Table 82. Innovent Biologics, Inc Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Innovent Biologics, Inc Monoclonal Antibodies for Primary Hypercholesterolemia Product
 Table 84. Innovent Biologics, Inc Recent Developments/Updates
 Table 85. Akeso Biopharma Co., Ltd Company Information
 Table 86. Akeso Biopharma Co., Ltd Description and Business Overview
 Table 87. Akeso Biopharma Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Akeso Biopharma Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Product
 Table 89. Akeso Biopharma Co., Ltd Recent Developments/Updates
 Table 90. Shanghai Junshi Biosciences Co., Ltd Company Information
 Table 91. Shanghai Junshi Biosciences Co., Ltd Description and Business Overview
 Table 92. Shanghai Junshi Biosciences Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Shanghai Junshi Biosciences Co., Ltd Monoclonal Antibodies for Primary Hypercholesterolemia Product
 Table 94. Shanghai Junshi Biosciences Co., Ltd Recent Developments/Updates
 Table 95. Key Raw Materials Lists
 Table 96. Raw Materials Key Suppliers Lists
 Table 97. Monoclonal Antibodies for Primary Hypercholesterolemia Distributors List
 Table 98. Monoclonal Antibodies for Primary Hypercholesterolemia Customers List
 Table 99. Monoclonal Antibodies for Primary Hypercholesterolemia Market Trends
 Table 100. Monoclonal Antibodies for Primary Hypercholesterolemia Market Drivers
 Table 101. Monoclonal Antibodies for Primary Hypercholesterolemia Market Challenges
 Table 102. Monoclonal Antibodies for Primary Hypercholesterolemia Market Restraints
 Table 103. Research Programs/Design for This Report
 Table 104. Key Data Information from Secondary Sources
 Table 105. Key Data Information from Primary Sources
 Table 106. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Monoclonal Antibodies for Primary Hypercholesterolemia
 Figure 2. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Share by Type: 2023 & 2030
 Figure 4. 140 mg/mL Product Picture
 Figure 5. 150 mg/mL Product Picture
 Figure 6. 300 mg/mL Product Picture
 Figure 7. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Value by Application (2024-2030) & (US$ Million)
 Figure 8. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Share by Application: 2023 & 2030
 Figure 9. Hospital
 Figure 10. Clinic
 Figure 11. Others
 Figure 12. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 13. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Size (2019-2030) & (US$ Million)
 Figure 14. Global Monoclonal Antibodies for Primary Hypercholesterolemia Sales (2019-2030) & (Units)
 Figure 15. Global Monoclonal Antibodies for Primary Hypercholesterolemia Average Price (US$/Unit) & (2019-2030)
 Figure 16. Monoclonal Antibodies for Primary Hypercholesterolemia Report Years Considered
 Figure 17. Monoclonal Antibodies for Primary Hypercholesterolemia Sales Share by Manufacturers in 2023
 Figure 18. Global Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Share by Manufacturers in 2023
 Figure 19. Global 5 and 10 Largest Monoclonal Antibodies for Primary Hypercholesterolemia Players: Market Share by Revenue in Monoclonal Antibodies for Primary Hypercholesterolemia in 2023
 Figure 20. Monoclonal Antibodies for Primary Hypercholesterolemia Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 21. Global Monoclonal Antibodies for Primary Hypercholesterolemia Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 22. North America Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Country (2019-2030)
 Figure 23. North America Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Country (2019-2030)
 Figure 24. United States Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Canada Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 26. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Country (2019-2030)
 Figure 27. Europe Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Country (2019-2030)
 Figure 28. Germany Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. France Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. U.K. Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Italy Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Russia Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Region (2019-2030)
 Figure 34. Asia Pacific Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Region (2019-2030)
 Figure 35. China Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. Japan Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. South Korea Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. India Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. Australia Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. China Taiwan Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Southeast Asia Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Latin America Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Country (2019-2030)
 Figure 43. Mexico Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Brazil Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Argentina Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Colombia Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Sales Market Share by Country (2019-2030)
 Figure 48. Middle East and Africa Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Market Share by Country (2019-2030)
 Figure 49. Turkey Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. Saudi Arabia Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. UAE Monoclonal Antibodies for Primary Hypercholesterolemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. Global Sales Market Share of Monoclonal Antibodies for Primary Hypercholesterolemia by Type (2019-2030)
 Figure 53. Global Revenue Market Share of Monoclonal Antibodies for Primary Hypercholesterolemia by Type (2019-2030)
 Figure 54. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Type (2019-2030)
 Figure 55. Global Sales Market Share of Monoclonal Antibodies for Primary Hypercholesterolemia by Application (2019-2030)
 Figure 56. Global Revenue Market Share of Monoclonal Antibodies for Primary Hypercholesterolemia by Application (2019-2030)
 Figure 57. Global Monoclonal Antibodies for Primary Hypercholesterolemia Price (US$/Unit) by Application (2019-2030)
 Figure 58. Monoclonal Antibodies for Primary Hypercholesterolemia Value Chain
 Figure 59. Monoclonal Antibodies for Primary Hypercholesterolemia Production Process
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global PCSK9 Targeted Drugs Market Research Report 2024
Global Anti PCSK9 Monoclonal Antibody Market Insights Forecast to 2030
Global Hepatocellular Carcinoma Monoclonal Antibody Market Research Report 2025
Global Monoclonal Antibodies for Alzheimer Disease Market Research Report 2024
Global Cholesterol Lowering Biologic Drugs Market Research Report 2024
Global Monoclonal Antibodies for Non small Cell Lung Cancer Market Research Report 2025
Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024
Global Aβ Monoclonal Antibody Drug Market Research Report 2024
Global Therapeutic Monoclonal Antibodies Drug Market Research Report 2024
Global Cholesterol lowering Statins Market Research Report 2024
Global Therapeutic Monoclonal Antibodies Market Research Report 2024
Global PCSK9 Antagonists Market Research Report 2024
Global Lipoprotein Lipase Monoclonal Antibody Market Research Report 2024
Global Cholesterol fighting Vaccine Market Research Report 2024
Global Cholesterol Vaccines Market Research Report 2024
Global Alirocumab Market Research Report 2024
Antihyperlipidemic Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Monoclonal Antibody for Gastric Cancer Market Research Report 2024
Global Nonstatin Cholesterol Medications Market Research Report 2024
Global Monoclonal Antibodies for Plaque Psoriasis Market Research Report 2024

RELATED REPORTS

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32E19705
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Cardiovascular Informations (CVIS) Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10A6248
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Pulmonary Arterial Hypertension (PAH) Medicine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-8I7059
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Heparin Calcium Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-15Y8668
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions